R E Buller

Summary

Affiliation: University of Iowa
Country: USA

Publications

  1. ncbi request reprint The influence of microvessel density on ovarian carcinogenesis
    Pamela J B Stone
    Holden Comprehensive Cancer Center, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Iowa Hospitals and Clinics, 200 Hawkins Drive, 4630 John Carver Pavilion, Iowa City, IA 52242, USA
    Gynecol Oncol 90:566-71. 2003
  2. ncbi request reprint Association between nonrandom X-chromosome inactivation and BRCA1 mutation in germline DNA of patients with ovarian cancer
    R E Buller
    Department of Pharmacology, The University of Iowa Hospitals and Clinics, Iowa City 52242 1009, USA
    J Natl Cancer Inst 91:339-46. 1999
  3. ncbi request reprint Long term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500
    Richard E Buller
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, The University of Iowa Hospitals and Clinics, Iowa City, Iowa 52242 1009, USA
    Cancer Gene Ther 9:567-72. 2002
  4. ncbi request reprint A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer
    Richard E Buller
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, The University of Iowa Hospitals and Clinics, Iowa City, Iowa 52242 1009, USA
    Cancer Gene Ther 9:553-66. 2002
  5. ncbi request reprint Failure of BRCA1 dysfunction to alter ovarian cancer survival
    Richard E Buller
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The University of Iowa Hospital and Clinic, Iowa City 52242 1009, USA
    Clin Cancer Res 8:1196-202. 2002
  6. ncbi request reprint The p53 mutational spectrum associated with BRCA1 mutant ovarian cancer
    R E Buller
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The University of Iowa Hospitals and Clinics, Iowa City, Iowa 52242 1009, USA
    Clin Cancer Res 7:831-8. 2001
  7. ncbi request reprint p53 Mutations and microsatellite instability in ovarian cancer: Yin and yang
    R E Buller
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The University of Iowa Hospitals and Clinics, Iowa City, 52242-1009, USA
    Am J Obstet Gynecol 184:891-902; discussion 902-3. 2001
  8. pmc Cyclosporin A reverses chemoresistance in patients with gynecologic malignancies
    A K Sood
    Department of Obstetrics and Gynecology, University of Iowa Hospitals and Clinics, Iowa City 52242, USA
    Neoplasia 1:118-22. 1999
  9. ncbi request reprint Distant metastases in ovarian cancer: association with p53 mutations
    A K Sood
    Department of Obstetrics and Gynecology, University of Iowa Hospitals and Clinics, Iowa City 52242, USA
    Clin Cancer Res 5:2485-90. 1999
  10. ncbi request reprint Ovarian cancer BRCA1 mutation detection: Protein truncation test (PTT) outperforms single strand conformation polymorphism analysis (SSCP)
    J P Geisler
    Division of Gynecologic Oncology, University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA
    Hum Mutat 18:337-44. 2001

Collaborators

Detail Information

Publications37

  1. ncbi request reprint The influence of microvessel density on ovarian carcinogenesis
    Pamela J B Stone
    Holden Comprehensive Cancer Center, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Iowa Hospitals and Clinics, 200 Hawkins Drive, 4630 John Carver Pavilion, Iowa City, IA 52242, USA
    Gynecol Oncol 90:566-71. 2003
    ....
  2. ncbi request reprint Association between nonrandom X-chromosome inactivation and BRCA1 mutation in germline DNA of patients with ovarian cancer
    R E Buller
    Department of Pharmacology, The University of Iowa Hospitals and Clinics, Iowa City 52242 1009, USA
    J Natl Cancer Inst 91:339-46. 1999
    ..This scenario could represent a previously unrecognized mechanism for development of hereditary cancers. We investigated whether such a mechanism might contribute to the development of hereditary ovarian cancers...
  3. ncbi request reprint Long term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500
    Richard E Buller
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, The University of Iowa Hospitals and Clinics, Iowa City, Iowa 52242 1009, USA
    Cancer Gene Ther 9:567-72. 2002
    ..The purpose of the present investigation was to evaluate the long-term follow-up of these heavily pretreated patients subsequent to SCH 58500 dosing...
  4. ncbi request reprint A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer
    Richard E Buller
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, The University of Iowa Hospitals and Clinics, Iowa City, Iowa 52242 1009, USA
    Cancer Gene Ther 9:553-66. 2002
    ..p.) alone and sequentially in combination with platinum-based chemotherapy, of patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer containing aberrant or mutant p53...
  5. ncbi request reprint Failure of BRCA1 dysfunction to alter ovarian cancer survival
    Richard E Buller
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The University of Iowa Hospital and Clinic, Iowa City 52242 1009, USA
    Clin Cancer Res 8:1196-202. 2002
    ..Many factors modify ovarian cancer survival. There are conflicting reports regarding survival of individuals with hereditary BRCA1-related ovarian cancer. None have controlled for other mechanisms of BRCA1 silencing in the control cohort...
  6. ncbi request reprint The p53 mutational spectrum associated with BRCA1 mutant ovarian cancer
    R E Buller
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The University of Iowa Hospitals and Clinics, Iowa City, Iowa 52242 1009, USA
    Clin Cancer Res 7:831-8. 2001
    ..Data from murine models and human BRCA1-related hereditary breast cancers suggest that both unique and specific BRCA1-associated p53 mutations may be found in BRCA1-related ovarian cancers...
  7. ncbi request reprint p53 Mutations and microsatellite instability in ovarian cancer: Yin and yang
    R E Buller
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The University of Iowa Hospitals and Clinics, Iowa City, 52242-1009, USA
    Am J Obstet Gynecol 184:891-902; discussion 902-3. 2001
    ..04). CONCLUSIONS: Microsatellite instability is a relatively common event in ovarian cancer and is dependent on marker selection. The p53 frameshift mutations do not appear to occur as a consequence of genomic instability...
  8. pmc Cyclosporin A reverses chemoresistance in patients with gynecologic malignancies
    A K Sood
    Department of Obstetrics and Gynecology, University of Iowa Hospitals and Clinics, Iowa City 52242, USA
    Neoplasia 1:118-22. 1999
    ..Cyclosporin A is well tolerated and has significant potential for reversal of chemoresistance in heavily pretreated patients with ovarian and uterine malignancies...
  9. ncbi request reprint Distant metastases in ovarian cancer: association with p53 mutations
    A K Sood
    Department of Obstetrics and Gynecology, University of Iowa Hospitals and Clinics, Iowa City 52242, USA
    Clin Cancer Res 5:2485-90. 1999
    ..These findings need to be carefully considered when choosing between regional versus systemic treatment modalities...
  10. ncbi request reprint Ovarian cancer BRCA1 mutation detection: Protein truncation test (PTT) outperforms single strand conformation polymorphism analysis (SSCP)
    J P Geisler
    Division of Gynecologic Oncology, University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA
    Hum Mutat 18:337-44. 2001
    ..9%. The concordance rate for the two screening tests was 88.9%. Only SSCP can detect missense mutations. PTT is a superior screening test for truncating BRCA1 mutations that are expected to be of clinical significance...
  11. ncbi request reprint Papillary serous carcinoma of the uterus: increased risk of subsequent or concurrent development of breast carcinoma
    J P Geisler
    Department of Obstetrics and Gynecology, University of Iowa Hospitals and Clinics, Iowa City, Iowa 52242, USA
    Gynecol Oncol 83:501-3. 2001
    ..001). CONCLUSION: Patients with UPSC have an increased risk of development of breast cancer as compared to patients with endometrioid adenocarcinoma of the uterus...
  12. ncbi request reprint Quality of life and mood in women receiving extensive chemotherapy for gynecologic cancer
    S K Lutgendorf
    University of Iowa, Department of Psychology, Iowa City, Iowa 52242, USA
    Cancer 89:1402-11. 2000
    ..Quality of life (QOL) and mood were investigated among women who had received intensive chemotherapy for at least 1 year for advanced gynecologic cancers. Relationships of coping styles to QOL and mood in these patients also were examined...
  13. doi request reprint BRCA2 alteration is important in clear cell carcinoma of the ovary
    M J Goodheart
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Iowa Hospitals and Clinics, Iowa City, Iowa 52242, USA
    Clin Genet 76:161-7. 2009
    ..5%, compared to only 40% for those patients without a BRCA2 alteration (p = 0.39). Alterations in BRCA2 gene sequence, copy number, or expression are extremely common in CCC and may contribute to a paradoxical better clinical outcome...
  14. ncbi request reprint Computed tomography in endometrial carcinoma
    J P Connor
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA
    Obstet Gynecol 95:692-6. 2000
    ..To determine the value of computed tomography (CT) scans for preoperatively detecting extrauterine-nodal disease and postoperative recurrent disease in patients with endometrial cancer...
  15. ncbi request reprint Cervical cancer diagnosed shortly after pregnancy: prognostic variables and delivery routes
    A K Sood
    Division of Gynecologic Oncology, University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA
    Obstet Gynecol 95:832-8. 2000
    ..To compare the prognoses of women diagnosed with cervical cancer during pregnancy with the prognoses of those diagnosed within 6 months after delivery and to assess the effect of vaginal delivery on recurrence risk and prognosis...
  16. ncbi request reprint Ovarian function after surgical treatment for cervical cancer
    T E Buekers
    Division of Gynecologic Oncology, University of Iowa Hospitals and Clinics, Iowa City, Iowa 52242, USA
    Gynecol Oncol 80:85-8. 2001
    ..The addition of UO or OT to this treatment reduces ovarian function appreciably. The addition of radiation therapy after OT dramatically shortens ovarian function...
  17. ncbi request reprint Application of the National Cancer Institute international criteria for determination of microsatellite instability in ovarian cancer
    A K Sood
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Holden Cancer Center, University of Iowa Hospitals and Clinics, 200 Hawkins Drive, Iowa City, IA 52242 1109, USA
    Cancer Res 61:4371-4. 2001
    ..MSI-H occurs in approximately 12% of invasive ovarian tumors. For optimal detection of microsatellite instability in ovarian cancer, an additional marker (NME1) may be required, along with the five recommended by the NCI...
  18. ncbi request reprint Malignant mixed mullerian tumor of the ovary and bilateral breast cancer: an argument for BRCA3, or a coincidental cluster of unconnected cancers?
    B A Burns
    Division of Gynecologic Oncology, Holden Comprehensive Cancer Center, Department of Pathology, University of Iowa, Iowa City, IA 52242, USA
    Gynecol Oncol 91:426-8. 2003
    ..Malignant mixed mullerian tumors (MMMTs) of the ovary are a rare, aggressive subtype of ovarian cancer without a clear relationship to familial breast-ovarian cancer syndromes...
  19. ncbi request reprint The role of p53 mutation in BRCA1-associated ovarian cancer
    S L Rose
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics, Iowa City, IA, USA
    Minerva Ginecol 54:201-9. 2002
    ..This review explores the evidence for BRCA1 and p53 interplay, and outlines the crucial role p53 may play in BRCA1-related ovarian cancer...
  20. pmc Molecular determinants of ovarian cancer plasticity
    A K Sood
    Department of Obstetrics and Gynecology, University of Iowa Hospitals and Clinics, 4630 JCP, 200 Hawkins Dr, Iowa City, IA 52242 1109, USA
    Am J Pathol 158:1279-88. 2001
    ..These results may offer new insights and molecular markers for consideration in ovarian cancer diagnosis and treatment strategies based on molecular vascular mimicry by aggressive tumor cells...
  21. ncbi request reprint Tunneled central venous catheters in a gynecologic oncology service: operative and short-term complications
    J P Geisler
    Division of Gynecologic Oncology, Indiana Women s Oncology, St Vincent Hospitals, Indianapolis, IN, USA
    Eur J Gynaecol Oncol 29:141-3. 2008
    ..To determine the difference in the immediate complication rate between placement of long-term central venous catheters (LTCVCs) by the percutaneous versus jugular venous cutdown method...
  22. ncbi request reprint Quality of life and mood in women with gynecologic cancer: a one year prospective study
    Susan K Lutgendorf
    Department of Psychology, University of Iowa, Iowa City, IA 52242, USA
    Cancer 94:131-40. 2002
    ..Quality of life (QOL) and mood were prospectively investigated during the first year of treatment among women with gynecologic cancers. Relationships of coping styles to QOL and mood were examined...
  23. ncbi request reprint The impact of p53 protein core domain structural alteration on ovarian cancer survival
    Stephen L Rose
    The Holden Comprehensive Cancer Center, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The University of Iowa Hospitals and Clinics, 200 Hawkins Drive, Iowa City, IA 52242, USA
    Clin Cancer Res 9:4139-44. 2003
    ..By evaluating ovarian cancer survival based upon a structure function analysis of the p53 protein, we tested the hypothesis that not all missense mutations are equivalent...
  24. ncbi request reprint Mismatch repair gene expression defects contribute to microsatellite instability in ovarian carcinoma
    John P Geisler
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA
    Cancer 98:2199-206. 2003
    ..The purpose of the current study was to determine the relation between MSI of ovarian carcinoma and MMR gene expression, hMLH1 and hMSH2 hypermethylation, and hMLH1 and hMSH2 null mutations...
  25. ncbi request reprint Sequential intraperitoneal topotecan and oral etoposide chemotherapy in recurrent platinum-resistant ovarian carcinoma: results of a phase II trial
    Anil K Sood
    Department of Gynecologic Oncology, University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 10:6080-5. 2004
    ..The purpose is to investigate the safety and efficacy of i.p. topotecan and oral etoposide as salvage treatment for patients with platinum-resistant ovarian or primary peritoneal cancer...
  26. ncbi request reprint The relationship of molecular markers of p53 function and angiogenesis to prognosis of stage I epithelial ovarian cancer
    Michael J Goodheart
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Iowa Hospital and Clinics, Iowa City, Iowa, USA
    Clin Cancer Res 11:3733-42. 2005
    ..Multiple angiogenic factors may influence tumor progression and metastasis. Several are modified by the p53 gene. We sought to identify molecular markers for high-risk stage I epithelial ovarian cancers...
  27. ncbi request reprint Serum CA 125 is an independent prognostic factor in cervical adenocarcinoma
    David P Bender
    Department of Obstetrics and Gynecology, Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics, USA
    Am J Obstet Gynecol 189:113-7. 2003
    ..The purpose of this study was to determine the prognostic significance of a pretreatment serum CA 125 value in patients who were diagnosed with adenocarcinoma of the cervix...
  28. ncbi request reprint Vascular endothelial growth factor and social support in patients with ovarian carcinoma
    Susan K Lutgendorf
    Department of Psychology, University of Iowa, Iowa City, Iowa 52242, USA
    Cancer 95:808-15. 2002
    ..This study examined relationships of social support and depressive symptoms with VEGF levels in preoperative patients with ovarian carcinoma...
  29. ncbi request reprint Frequency of BRCA1 dysfunction in ovarian cancer
    John P Geisler
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Holden Comprehensive Cancer Center, University of Iowa, Iowa City 52242, USA
    J Natl Cancer Inst 94:61-7. 2002
    ..Therefore, we developed an efficient strategy to detect various types of BRCA1 dysfunction and also determined the relative frequency of BRCA1 dysfunction in ovarian cancer...
  30. ncbi request reprint Ovarian cancer p53 mutation is associated with tumor microvessel density
    Michael J Goodheart
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics, Iowa City, Iowa 52242, USA
    Gynecol Oncol 86:85-90. 2002
    ..The objective of this study was to investigate the relationship between microvessel density, as measured by CD31 staining, and histopathologic factors as well as p53 tumor suppressor gene mutation in ovarian cancer...
  31. ncbi request reprint Preoperative CA 125 levels: an independent prognostic factor for epithelial ovarian cancer
    Brian C Cooper
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The University of Iowa Hospitals and Clinics, Iowa City 52242, USA
    Obstet Gynecol 100:59-64. 2002
    ..To estimate the association of preoperative CA 125 levels with outcome in primary ovarian cancer patients...
  32. ncbi request reprint Inactivation of BRCA1 and BRCA2 in ovarian cancer
    Jeffrey L Hilton
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Holden Comprehensive Cancer Center, Iowa City, IA, USA
    J Natl Cancer Inst 94:1396-406. 2002
    ..Our goal was to characterize BRCA2 mutations and mRNA expression in a group of ovarian tumors previously evaluated for BRCA1 mutations and mRNA expression...
  33. ncbi request reprint Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer
    Brian C Cooper
    Division of Gynecologic Oncology, Departments of Obstetrics and Gynecology, Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics, Iowa City, Iowa 52242, USA
    Clin Cancer Res 8:3193-7. 2002
    ..VEGF levels were determined using an ELISA (R&D Systems, Minneapolis, MN)...
  34. ncbi request reprint p53 null mutations are associated with a telomerase negative phenotype in ovarian carcinoma
    Anil K Sood
    Department of Gynecologic Oncology, University of Texas, M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 440, Houston, TX 77030 USA
    Cancer Biol Ther 1:511-7. 2002
    ..03). Ovarian cancers with a p53 null mutation are more likely to lack telomerase activity. This may have implications for therapeutic approaches based on telomerase...
  35. ncbi request reprint p21 expression predicts outcome in p53-null ovarian carcinoma
    Stephen L Rose
    Holden Comprehensive Cancer Center, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The University of Iowa Hospitals and Clinics, 200 Hawkins Drive, Iowa City, IA 52242, USA
    Clin Cancer Res 9:1028-32. 2003
    ..We hypothesize that such an analysis may be useful in prognosticating outcome for individuals diagnosed with epithelial ovarian cancer...
  36. ncbi request reprint Roles of KLF6 and KLF6-SV1 in ovarian cancer progression and intraperitoneal dissemination
    Analisa Difeo
    Department of Human Genetics, Mount Sinai School of Medicine, 1425 Madison Avenue, New York, New York 10029, USA
    Clin Cancer Res 12:3730-9. 2006
    ..We investigated the role of the KLF6 tumor suppressor gene and its alternatively spliced isoform KLF6-SV1 in epithelial ovarian cancer (EOC)...
  37. ncbi request reprint Prolonged oral etoposide in recurrent or advanced non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study
    Peter G Rose
    Division of Gynecologic Oncology, Case Western Reserve University, University Hospitals of Cleveland, OH 44106, USA
    Gynecol Oncol 89:267-70. 2003
    ..To evaluate prolonged oral etoposide in nonsquamous cell carcinoma of the cervix, the current phase II trial was conducted...